Interim Trial Results Show Lasmiditan Is Well Tolerated in Migraine Treatment
Researchers found data that showed lasmiditan to be safe in the treatment of migraines.
Researchers found data that showed lasmiditan to be safe in the treatment of migraines.
Multiple sclerosis seems to prevent individuals from realizing their full potential at home and work, with fatigue being overwhelmingly identified as the cause, according to preliminary findings presented at ECTRIMS 2019.
The study compared general and giant cell arteritis-specific characteristics in patients with and without visual symptoms, and examined the role of diagnostic delay in patients with giant cell arteritis experiencing current visual symptoms.
Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.
Investigators sought to determine whether a second dose of lasmiditan can efficiently and safely treat migraine.
Researchers sought to determine whether demographics and initiation of acute medication use could predict initiation of preventive migraine medication.
Researchers evaluated survey results to determine the prevalence and impact of perceived bullying during residency.
In patients with ischemic penumbra and blood-brain barrier disruption, hyperoxygenation therapy may mitigate ischemia and remove air.
Researchers used information they gleaned from a systematic review of articles focused on discharge instructions in the ED to assess differences in comprehension or recall of verbal, verbal plus written, and verbal plus video discharge instructions.
The relatively recent submissions by state policymakers requesting to close their Medicaid formularies highlighted ethical concerns regarding access and treatment of patients who are poor or vulnerable.